COMPANY

Triumvira Immunologics

HQ: San Francisco, CA source · triumvira.com ↗

Location: San Francisco, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: HER2 Positive Gastric Cancer Metastatic HER2 Positive Gastroesophageal Junction Cancer B-Cell Lymphoma TAC01-HER2 TAC01-CLDN18.2 TAC01-CD19

Timeline

Aug 23, 2023 Trial start Phase 1/Phase 2: TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) source ↗
Apr 19, 2021 Trial start Phase 1/Phase 2: TAC T-cells for the Treatment of HER2-positive Solid Tumors source ↗
2020-05 Trial start Phase 1/Phase 2: Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma source ↗

Aug 1, 2027 (ESTIMATED) · Phase 1/Phase 2 · TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) · NCT05862324

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT04727151	TAC T-cells for the Treatment of HER2-positive Solid Tumors	Phase 1/Phase 2	Terminated	Apr 19, 2021	Dec 17, 2023 (actual)
NCT05862324	TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)	Phase 1/Phase 2	Active, not recruiting	Aug 23, 2023	Aug 1, 2027 (estimated)
NCT03880279	Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma	Phase 1/Phase 2	Withdrawn	2020-05	2022-04 (estimated)